Patents by Inventor Jennifer Pitzen

Jennifer Pitzen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS
    Publication number: 20240101577
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: February 17, 2023
    Publication date: March 28, 2024
    Inventors: Elena S. KOLTUN, Naing N. AAY, Andreas BUCKL, Kevin T. MELLEM, Brian R. BLANK, Jennifer PITZEN, Gang WANG, Ashutosh S. JOGALEKAR, Walter S. WON, Christos TZITZILONIS, Jie Jack LI, Adrian Liam GILL, James Joseph CREGG
  • RAS INHIBITORS
    Publication number: 20230374035
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: February 6, 2023
    Publication date: November 23, 2023
    Inventors: Elena S. KOLTUN, James CREGG, Naing AAY, Andreas BUCKL, Adrian L. GILL, James AGGEN, G. Leslie BURNETT, Jennifer PITZEN, Daniel M. WHALEN, John E. KNOX, Yang LIU
  • Ras inhibitors
    Patent number: 11739074
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: August 29, 2023
    Assignee: Revolution Medicines, Inc.
    Inventors: James Aggen, G. Leslie Burnett, Jennifer Pitzen, Adrian L. Gill, Elena S. Koltun, James Cregg, Andreas Buckl, Anne V. Edwards, John E. Knox
  • Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
    Patent number: 11739093
    Abstract: The present disclosure is directed to compounds of Formula IV: as inhibitors of SHP2 and their use in the treatment of diseases associated with SHP2. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: August 29, 2023
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Brian R. Blank, Jennifer Pitzen, Gang Wang, Walter S. Won, Christos Tzitzilonis, Jie Jack Li, Elena S. Koltun, Naing Aay, Andreas Buckl, Kevin Mellem, Christopher Semko, Ash Jogalekar, Gert Kiss, Adrian Gill
  • RAS INHIBITORS
    Publication number: 20230234929
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: January 30, 2023
    Publication date: July 27, 2023
    Inventors: Elena S. KOLTUN, James Cregg, Adrian L. Gill, James Aggen, G. Leslie Burnett, Jennifer Pitzen, Andreas Buckl, John E. Knox, Yang Liu
  • C26-linked rapamycin analogs as mTOR inhibitors
    Patent number: 11685749
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: June 27, 2023
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Christopher Michael Semko, Gang Wang, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Micah James Evans Gliedt, Jennifer Pitzen, Julie Chu-Li Lee, Walter Won, Arun P. Thottumkara, Adrian Liam Gill
  • Polycyclic compounds as allosteric SHP2 inhibitors
    Patent number: 11673901
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: June 13, 2023
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Elena S. Koltun, Naing N. Aay, Andreas Buckl, Kevin T. Mellem, Brian R. Blank, Jennifer Pitzen, Gang Wang, Ashutosh S. Jogalekar, Walter S. Won, Christos Tzitzilonis, Jie Jack Li, Adrian Liam Gill, James Joseph Cregg
  • Polycyclic compounds as allosteric SHP2 inhibitors
    Patent number: 11634435
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: April 25, 2023
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Elena S. Koltun, Naing N. Aay, Andreas Buckl, Kevin T. Mellem, Brian R. Blank, Jennifer Pitzen, Gang Wang, Ashutosh S. Jogalekar, Walter S. Won, Christos Tzitzilonis, Jie Jack Li, Adrian Liam Gill, James Joseph Cregg
  • COVALENT RAS INHIBITORS AND USES THEREOF
    Publication number: 20230100838
    Abstract: The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological processes including Ras, and their uses in the treatment of cancers.
    Type: Application
    Filed: May 26, 2022
    Publication date: March 30, 2023
    Inventors: Jennifer PITZEN, James AGGEN, G. Leslie BURNETT, Adrian L. GILL, Christopher SEMKO, Anne V. EDWARDS, Micah James GLIEDT, Gert KISS, Ashutosh JOGALEKAR, John E. KNOX, Andreas BUCKL, Elena S. KOLTUN
  • RAPAMYCIN ANALOGS AS MTOR INHIBITORS
    Publication number: 20230093861
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: March 11, 2022
    Publication date: March 30, 2023
    Inventors: James Bradley AGGEN, Arun P. THOTTUMKARA, G. Leslie BURNETT, Micah James Evans GLIEDT, Gert KISS, Walter WON, Julie Chu-Li LEE, Adrian Liam GILL, Christopher SEMKO, Jennifer PITZEN, Gang WANG, Nidhi TIBREWAL
  • C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
    Publication number: 20230055672
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: April 29, 2022
    Publication date: February 23, 2023
    Inventors: Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
  • RAS INHIBITORS
    Publication number: 20220396589
    Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: May 5, 2022
    Publication date: December 15, 2022
    Inventors: Andreas BUCKL, G. Leslie BURNETT, James CREGG, Anne V. EDWARDS, Adrian L. GILL, John E. KNOX, Elena S. KOLTUN, Jennifer PITZEN, Christopher SEMKO
  • C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS
    Publication number: 20220340596
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: October 30, 2020
    Publication date: October 27, 2022
    Inventors: Christopher Michael SEMKO, Gang WANG, G. Leslie BURNETT, James Bradley AGGEN, Gert KISS, James Joseph CREGG, Micah James Evans GLIEDT, Jennifer PITZEN, Julie Chu-Li LEE, Walter WON, Arun P. THOTTUMKARA, Adrian Liam GILL
  • C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
    Patent number: 11364300
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: June 21, 2022
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Jennifer Pitzen, G. Leslie Burnett, James Bradley Aggen
  • C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
    Publication number: 20210338824
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: October 28, 2020
    Publication date: November 4, 2021
    Inventors: Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
  • RAS INHIBITORS
    Publication number: 20210130369
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Inventors: Elena S. KOLTUN, James CREGG, Naing AAY, Andreas BUCKL, Adrian L. GILL, James AGGEN, G. Leslie BURNETT, Jennifer PITZEN, Daniel M. WHALEN, John E. KNOX, Yang LIU
  • RAS INHIBITORS
    Publication number: 20210130303
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Inventors: Elena S. KOLTUN, James CREGG, Adrian L. GILL, James AGGEN, G. Leslie BURNETT, Jennifer PITZEN, Andreas BUCKL, John E. KNOX, Yang LIU
  • RAS INHIBITORS
    Publication number: 20210130326
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Inventors: James AGGEN, G. Leslie BURNETT, Jennifer PITZEN, Adrian L. GILL, Elena S. KOLTUN, James CREGG, Andreas BUCKL, Anne V. EDWARDS, Christopher SEMKO, Micah James GLIEDT, John E. KNOX
  • C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
    Patent number: 10980889
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: April 20, 2021
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
  • RAPAMYCIN ANALOGS AS MTOR INHIBITORS
    Publication number: 20210094975
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: October 30, 2019
    Publication date: April 1, 2021
    Inventors: James Bradley AGGEN, Arun P. THOTTUMKARA, G. Leslie BURNETT, Micah James Evans GLIEDT, Gert KISS, Walter WON, Julie Chu-Li LEE, Adrian Liam GILL, Christopher SEMKO, Jennifer PITZEN, Gang WANG, Nidhi TIBREWAL